Insmed Q3 revenue $142.3M (+52% YoY); net loss $370M; BRINSUPRI launch $28.1M; raises ARIKAYCE guidance

INSMED Inc

2025-Q3 EPS reported -$4.89 revenue$342,580,000

ARIKAYCE global revenue $114.3M (+22% YoY); 2025 guidance raised to $420M-$430M.
BRINSUPRI (brensocatib) launched post-FDA approval, Q3 revenue $28.1M; EU positive CHMP opinion.
Net loss $370M ($1.75/shr) vs $220.5M ($1.27/shr) YoY, driven by higher R&D and SG&A for launch.
Cash and securities $1.7B; plans continued investment across pipeline (brensocatib, TPIP, gene therapy).
Upcoming catalysts: Ph2b BiRCh data (CRSsNP) by early Jan 2026; CEDAR (HS) data H1 2026; PALM-ILD start Q4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.